Zencurix Signs Licensing Agreement with Bio-Rad to "Lead the Digital PCR Diagnostic Market"

[Asia Economy Reporter Hyungsoo Park] Molecular diagnostics company GenCurix announced on the 27th that it has signed a contract with global diagnostic equipment company Bio-Rad to sell digital gene amplification (PCR) equipment and related consumables domestically.

GenCurix expects to provide general hospitals with ▲ its companion diagnostic DropFlex products ▲ Bio-Rad's digital PCR diagnostic equipment and consumables ▲ companion diagnostic full-package solutions. GenCurix, which develops and sells various digital PCR-based diagnostic products, plans to aggressively target the market by collaborating with Bio-Rad, a global leader in the digital PCR field.

A company official stated, "Bio-Rad needed a partner with the technical capability to develop various test contents to expand sales of digital PCR equipment," adding, "They highly evaluated GenCurix's competitiveness, which has continuously invested in research and development in this field for a long time."

He continued, "Bio-Rad will play the role of building the best diagnostic equipment platform, while GenCurix will be responsible for developing various test contents that can be utilized on the digital PCR platform."

Digital PCR has superior sensitivity compared to real-time gene amplification (RT-PCR), well known as a COVID-19 diagnostic method, making it advantageous for small tissue biopsies or liquid biopsy diagnostic tests. Bio-Rad conducted training on GenCurix's digital PCR diagnostic products for sales and marketing personnel in major Asian countries. Bio-Rad also shows strong willingness and interest in overseas sales. They plan to strengthen collaboration starting with the licensing contract.

Founded in 1952, Bio-Rad is a global diagnostic company with world-class technology in the molecular diagnostics equipment field. It developed the ‘CFX96,’ the most widely used equipment among COVID-19 diagnostic kits. It also holds a dominant market share as number one in the digital PCR field.

A GenCurix official emphasized, "While continuing efforts to increase product sales, we will also accelerate the approval process for new products and cooperate more closely with Bio-Rad."